- Axsome Therapeutics (NASDAQ:AXSM) -43% on Q2 earnings release and on likely delay in potential approval of AXS-05; depression study meets endpoints
- BioVie (NASDAQ:BIVI) -35% after secures $20M via equity raise
- Aterian (NASDAQ:ATER) -31% on Q2 earnings release
- bluebird bio (NASDAQ:BLUE) -21% on Q2 earnings release
- Epizyme (NASDAQ:EPZM) -14% on Q2 earnings release
- Eton Pharmaceuticals (NASDAQ:ETON) -13% after FDA decision on Eton's topiramate delayed to November.
- Kaixin Auto (NASDAQ:KXIN) -12%
- Avaya Holdings (NYSE:AVYA) -8% on FQ3 earnings release
- Elanco Animal Health (NYSE:ELAN) -7% on Q2 earnings release
- Nuwellis (NASDAQ:NUWE) -6%.
- Taoping (NASDAQ:TAOP) -6%.
- Village Farms International (NASDAQ:VFF) -5% on Q2 earnings release